SLC5A2 and chronic kidney disease: Even in patients with stage 2 chronic kidney disease, with an estimated glomerular filtration rate (eGFR) of ≥ 60 to < 90 mL/min/1.73 m2, the glucose-lowering efficacy of SGLT-2 inhibitor is lower than that in those with a normal kidney function, with an eGFR of ≥ 90 mL/min/1.73 m2 [2].